anti-GPC3 T cell-engaging antibody AZD9793

A T-cell engaging (TCE) asymmetric trispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3 TCE antibody AZD9793 targets and binds to GPC3 expressed on tumor cells and to CD3 and CD8 antigens on CD8-positive T lymphocytes. This activates and redirects CTLs to GPC3-expressing tumor cells, which results in the CTL-mediated death of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells. GPC3 plays an important role in tumor cell proliferation in various tumor cell types.